| Literature DB >> 34012707 |
Vidya Rao1, Rajiv Kumar1, Sathyanarayanan Rajaganesan1, Swapnil Rane1, Gauri Deshpande1, Subhash Yadav1, Asawari Patil1, Trupti Pai1, Santosh Menon1, Aekta Shah1, Katha Rabade1, Mukta Ramadwar1, Poonam Panjwani1, Neha Mittal1, Ayushi Sahay1, Bharat Rekhi1, Munita Bal1, Uma Sakhadeo1, Sumeet Gujral1, Sangeeta Desai1.
Abstract
BACKGROUND: The COVID-19 pandemic accelerated the widespread adoption of digital pathology (DP) for primary diagnosis in surgical pathology. This paradigm shift is likely to influence how we function routinely in the postpandemic era. We present learnings from early adoption of DP for a live digital sign-out from home in a risk-mitigated environment.Entities:
Keywords: Digital pathology; remote reporting; whole-slide imaging
Year: 2021 PMID: 34012707 PMCID: PMC8112339 DOI: 10.4103/jpi.jpi_72_20
Source DB: PubMed Journal: J Pathol Inform
Figure 1Digital environment for reporting from remote site. SRS: Synoptic reporting system, HIS: Hospital information system, LIS: Laboratory information system, EMR: Electronic medical record
Distribution of cases and deferrals by subspecialty
| Subspecialty | Total cases | Deferred | Cases digitally signed out | Parts | Slides |
|---|---|---|---|---|---|
| HN | 214 | 6 | 208 | 220 | 361 |
| BR | 87 | 4 | 83 | 91 | 366 |
| GI | 122 | 7 | 115 | 117 | 225 |
| TH | 82 | 5 | 77 | 77 | 191 |
| GY | 52 | 3 | 49 | 53 | 168 |
| GU | 25 | 1 | 24 | 47 | 74 |
| BST | 12 | 1 | 11 | 11 | 41 |
| Total | 594 | 27 | 567 | 616 | 1426 |
HN: Head and neck, BR: Breast, GI: Gastrointestinal, TH: Thoracic pathology, BST: Bone and soft tissue, GY: Gynecologic pathology, GU: Genitourinary
Deferred cases
| Site | Reason |
|---|---|
| Oral cavity, esophagus | Invasion assessment of a scant focus (2) |
| Lung | Unusual morphology of metastasis in a known case |
| Oral cavity, cervix | Grading of dysplasia (2) |
| Mediastinum | Grey zone between Hodgkin lymphoma and primary mediastinal B-cell lymphoma |
| Hard palate, urinary bladder, lung | Grading of tumor (3) |
| Ascitic fluid | Scant atypical cells (3) |
| Gallbladder | Scant focus of adenocarcinoma |
| Colorectum, lung, nasal cavity | Poorly differentiated malignant tumor (3) |
| Colorectum | Inflammatory atypia versus dysplasia |
| Ascitic fluid | Presence of nucleated RBCs |
| Liver biopsy | Carcinoma inconclusive on IHC |
| Breast | Fixation artifacts |
| Breast | IHC internal control unsatisfactory (2) |
| Breast, lung | Pixelation and WSI latency (2) |
| Lung | Neoplastic versus reactive spindle cell proliferation |
| Lung | Benign versus low-grade neoplasm |
| Endometrium | Proliferative changes versus hyperplasia |
*Numbers in brackets indicate number of cases with the same reason for deferral. ESI: Whole-slide imaging, IHC: Immunohistochemistry, RBCs: Red blood cells, WSI: Whole-slide imaging
Distribution of subspecialized and general pathologists across subspecialties
| Subspecialty | Pathologists |
|---|---|
| HN | A*, E, G*, I*, J, L*, N*, P, Q |
| GI | C, E, G*, H*, J*, N, O |
| BR | A*, B*, F, K*, O |
| TH | C, F, J*, P*, R |
| GY | D*, E, I*, K, M*, Q, R, U |
| GU | F, K*, M*, R |
| BST | C, D*, E, N |
*Indicates subspecialty expertise. HN: Head and neck, BR: Breast, GI: Gastrointestinal, TH: Thoracic pathology, BST: Bone and soft tissue, GY: Gynecologic pathology, GU: Genitourinary
Subspecialties with distribution of cases by site and corresponding diagnostic parts
| Subspecialty | Site | Total parts |
|---|---|---|
| HN | Oral cavity | 168 |
| Oropharynx | 10 | |
| Larynx | 9 | |
| Nasopharynx | 1 | |
| Maxilla | 1 | |
| Orbit, eye | 3 | |
| Lymph node | 10 | |
| Lung | 5 | |
| External auditory canal | 2 | |
| Temporal region | 4 | |
| Chest wall | 2 | |
| Skin | 2 | |
| Thyroid | 1 | |
| Others | 2 | |
| TH | Lung | 34 |
| Pleural fluid | 11 | |
| Lymph node | 12 | |
| Mediastinum | 1 | |
| Rib | 3 | |
| Abdominal wall | 1 | |
| Scapula | 1 | |
| Esophagus, GE junction | 9 | |
| Liver | 5 | |
| GI | Colorectum | 11 |
| Gallbladder | 19 | |
| Ampulla/periampullary region | 3 | |
| Pancreas | 8 | |
| Liver | 27 | |
| Stomach, GE junction | 5 | |
| Ascitic fluid | 15 | |
| Abdominopelvic region | 9 | |
| Omentum | 4 | |
| Lymph node | 8 | |
| Lung, pleural fluid | 4 | |
| Ovary | 2 | |
| Esophagus | 1 | |
| Duodenum | 1 | |
| GY | Cervix, endocervix, vaginal vault | 23 |
| Ovary, omentum | 6 | |
| Endometrium | 2 | |
| Ascitic fluid | 16 | |
| Lymph node | 2 | |
| Kidney | 1 | |
| Pleural fluid | 3 | |
| BR | Breast | 62 |
| Skin | 6 | |
| Lung | 2 | |
| Pleural fluid | 3 | |
| Chest wall | 1 | |
| Lymph node | 4 | |
| Abdominal wall | 1 | |
| Ascitic fluid | 4 | |
| BR (Contd.) | Omentum | 2 |
| Liver | 4 | |
| Endometrium | 1 | |
| Esophagus | 1 | |
| GU | Urinary bladder, ureteric orifice | 24 |
| Kidney | 5 | |
| Penis | 2 | |
| Prostate | 12 | |
| Iliac fossa | 1 | |
| Lung | 1 | |
| Endometrium | 1 | |
| Rectum | 1 | |
| BST | Bone | 7 |
| Soft tissue | 1 | |
| Lymph node | 1 | |
| Skin | 1 | |
| Lung | 1 |
HN: Head and neck, BR: Breast, GI: Gastrointestinal, TH: Thoracic pathology, BST: Bone and soft tissue, GY: Gynecologic pathology, GU: Genitourinary, GE: Gastroesophageal
Subspecialties and distribution of individual parts by diagnostic category
| Subspecialty | Diagnostic category | Total parts |
|---|---|---|
| HN | Negative for malignancy | 22 |
| Reactive lymphoid tissue | 2 | |
| Inflammation including granulomatous type | 15 | |
| Benign | 5 | |
| Dysplasia | 10 | |
| Atypical squamous proliferation | 8 | |
| Suspicious for carcinoma | 6 | |
| Carcinoma | 138 | |
| Malignancy/metastasis | 11 | |
| Necrosis only/inadequate/nonrepresentative biopsy | 3 | |
| BR | Negative for malignancy | 3 |
| Inflammation | 3 | |
| Benign | 9 | |
| DCIS | 1 | |
| Invasive breast carcinoma | 53 | |
| Malignancy/metastasis | 21 | |
| Necrosis | 1 | |
| GI | Negative for malignancy | 6 |
| Inflammation including granulomatous type | 4 | |
| Benign | 3 | |
| Suspicious for adenocarcinoma | 1 | |
| Malignancy/ metastasis | 101 | |
| Inadequate | 1 | |
| GY | Benign | 3 |
| CIN/CIS | 2 | |
| Suspicious for metastasis | 1 | |
| Metastasis | 19 | |
| Carcinoma | 25 | |
| Inflammation | 3 | |
| BST | Granuloma | 1 |
| Sarcoma | 3 | |
| Metastasis | 5 | |
| Plasma cell neoplasm | 2 | |
| TH | Negative for malignancy | 3 |
| Reactive | 1 | |
| Granuloma | 5 | |
| Carcinoma | 37 | |
| Malignancy/metastasis | 31 | |
| GU | Negative for malignancy | 11 |
| Necrosis | 1 | |
| Inflammation | 2 | |
| Carcinoma | 25 | |
| Atypical small acinar proliferation | 1 | |
| Germ cell tumor | 1 | |
| Benign | 6 |
HN: Head and neck, BR: Breast, GI: Gastrointestinal, TH: Thoracic pathology, BST: Bone and soft tissue, GY: Gynepathology, GU: Genitourinary, DCIS: Ductal carcinoma in-situ, CIN/CIS: Cervical intraepithelial neoplasia/Carcinoma in-situ
Discordances between whole-slide imaging and glass reads
| Site/diagnosis | WSI | Glass | Reference | Discordance | |
|---|---|---|---|---|---|
| 1 | High-grade urothelial carcinoma of urinary bladder | Lamina propria invasion is not seen | Focal lamina propria invasion is seen | Lamina propria invasion is seen | Minor |
| 2 | Invasive breast carcinoma | HER2/neu equivocal (score 2+) by IHC | HER2/neu negative (score 1+) by IHC | HER2/neu negative (score 1+) by IHC | Minor |
| 3 | Breast | Invasive breast carcinoma Grade 2. Modified RB score 3+2=2=7 | Invasive breast carcinoma Grade 3. Modified RB score 3+3+2=8 | Invasive breast carcinoma Grade 3. Modified RB score 3+3+2=8 | Minor |
| 4 | Lung | Adenocarcinoma | Adenosquamous carcinoma | Adenosquamous carcinoma | Minor |
| 5 | Oral cavity | Atypical squamous proliferation, suspicious for squamous cell carcinoma | Squamous cell carcinoma | Squamous cell carcinoma | Minor |
| 6 | Oral cavity | Atypical squamous proliferation, suspicious for squamous cell carcinoma | Squamous cell carcinoma | Squamous cell carcinoma | Minor |
| 7 | Oral cavity | Atypical squamous proliferation, suspicious for squamous cell carcinoma | Consistent with squamous cell carcinoma | Squamous cell carcinoma | Minor |
WSI: Whole-slide imaging, IHC: Immunohistochemistry, HER2: Human epidermal growth factor receptor 2, RB: Richardson-Bloom